Catalyst Biosciences (NASDAQ: CBIO) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Earnings and Valuation

This table compares Catalyst Biosciences and Anika Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Catalyst Biosciences $400,000.00 75.96 -$16.94 million ($13.12) -0.54
Anika Therapeutics $103.38 million 7.61 $32.54 million $2.13 25.19

Anika Therapeutics has higher revenue and earnings than Catalyst Biosciences. Catalyst Biosciences is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Catalyst Biosciences has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.

Profitability

This table compares Catalyst Biosciences and Anika Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Catalyst Biosciences -2,438.50% -91.67% -55.28%
Anika Therapeutics 28.23% 13.40% 12.41%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Catalyst Biosciences and Anika Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Catalyst Biosciences 0 0 2 0 3.00
Anika Therapeutics 0 0 1 0 3.00

Catalyst Biosciences currently has a consensus price target of $10.50, suggesting a potential upside of 48.94%. Anika Therapeutics has a consensus price target of $57.00, suggesting a potential upside of 6.24%. Given Catalyst Biosciences’ higher probable upside, research analysts plainly believe Catalyst Biosciences is more favorable than Anika Therapeutics.

Institutional and Insider Ownership

31.5% of Catalyst Biosciences shares are owned by institutional investors. Comparatively, 84.9% of Anika Therapeutics shares are owned by institutional investors. 5.0% of Catalyst Biosciences shares are owned by company insiders. Comparatively, 6.6% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Anika Therapeutics beats Catalyst Biosciences on 8 of the 12 factors compared between the two stocks.

About Catalyst Biosciences

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

About Anika Therapeutics

Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company’s therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company’s ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.

Receive News & Ratings for Catalyst Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.